WB-DW-MRI vs CHOLINE-PET/CT for Selecting Treatments in Recurrent Prostate Cancer

NCT ID: NCT02858128

Last Updated: 2016-08-09

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 46 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2015-03-31

Brief Summary

The purpose of this study is to determine the effectiveness of whole-body diffusion-weighted magnetic resonance imaging (WB-DW- MRI) in detecting metastases by comparing the results with those from choline-positron emission tomography-computed tomography (choline-PET/CT) in patients with metastatic/oligometastatic prostate cancer. Patients with this disease profile who could benefit from treatment with stereotactic body radiation therapy (SBRT) were selected and their responses to these techniques were rated.

Detailed Description

This was a prospective, controlled, unicentric study, involving 46 consecutive patients from our centre who presented biochemical relapse after adjuvant, salvage or radical treatment with external beam radiotherapy, or brachytherapy. After initial tests ( bone scintigraphy, CT, pelvic MRI) 35 patients with oligometastases or without them were selected. 11 patients with multiple metastases were excluded from the study. WB-DW- MRI and choline-PET/CT was then performed on each patient within one week. The results were interpreted by specialists in nuclear medicine and MRI. If they were candidates for treatment with ablative SBRT (SABR) they were then evaluated every three months with both tests.

Conditions

Prostate Cancer

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Interventions

IMAGING STUDY

Choline-PET/CT versus NMRscan comparative study

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Prostate cancer histologic diagnostic after one treatment
• 5 o less lessions
• Asimptomatic lessions
• Informed Consent Form signed

Exclusion Criteria

• Not capability to perform NMR os CT/PET scans

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Hospital Provincial de Castellon

OTHER

Sponsor Role: lead

Responsible Party

Antonio J Conde Moreno

MD PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Antonio J Conde Moreno, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital Provincial de Castellon

References

Conde-Moreno AJ, Herrando-Parreno G, Muelas-Soria R, Ferrer-Rebolleda J, Broseta-Torres R, Cozar-Santiago MP, Garcia-Pinon F, Ferrer-Albiach C. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer. Clin Transl Oncol. 2017 May;19(5):553-561. doi: 10.1007/s12094-016-1563-4. Epub 2016 Oct 31.

Reference Type: DERIVED

PMID: 27796820 (View on PubMed)

Other Identifiers

PRV00024

Identifier Type: -

Identifier Source: org_study_id